Low‐density lipoprotein (LDL) cholesterol‐lowering drugs commonly prescribed for the prevention and management of cardiovascular disease, including 3‐Hydroxy‐3‐methylglutaryl coenzyme A reductase inhibitors (HMGCR; target of statins), Niemann‐Pick C1‐Like 1 (NPC1L1; target of ezetimibe) and proprotein convertase subtilisin/kexin type 9 (PCSK9; target of PCSK9 inhibitors). Here, PCSK9 is linked to cardiovascular disorder.